Introduction

Major depressive disorder (MDD) is a common mental disease, associated with a debilitating condition and high prevalence. Although the underlying mechanism of MDD remains to be elucidated, several factors, including social, biological, and psychological factors, have been associated with disease pathogenesis. Metabolomics can provide new insights into the prognosis, treatment response, and related biomarkers associated with MDD at the metabolic level.

Areas covered

In this review, we investigated the metabolic changes identified in different bio-samples from animal models of depression and MDD patients. Moreover, we summarized the metabolites associated with antidepressant treatment responses. Keywords used for the literature searches were ‘depression’ [MeSH] and ‘metabolomics’ [MeSH], in PubMed.

Expert opinion

Metabolomic evidence in humans has indicated that amino acid metabolism, energy metabolism, and lipid metabolism are the primary metabolic alterations that are observed in the etiology of MDD, and animal models serve as an important theoretical reference in this field. Metabolomics has shed new light on the pathogenic mechanisms and treatment responses during MDD; however, study results are not always consistent. The application of metabolomic results to clinical practice will require the integration of different biological samples and other omics studies, as well as the clinical validation of study findings.

中文翻译：

---

代谢组学在重大抑郁症和相关疾病研究和治疗中的潜力。

介绍

重度抑郁症（MDD）是一种常见的精神疾病，伴有虚弱的状况和较高的患病率。尽管尚需阐明MDD的潜在机制，但多种因素，包括社会，生物学和心理因素，都与疾病的发病机理有关。代谢组学可以在代谢水平上提供与MDD相关的预后，治疗反应和相关生物标志物的新见解。

覆盖区域

在这篇综述中，我们调查了在抑郁症和MDD患者动物模型的不同生物样品中鉴定出的代谢变化。此外，我们总结了与抗抑郁药治疗反应有关的代谢产物。在PubMed中，用于文献检索的关键词是“抑郁” [MeSH]和“代谢代谢学” [MeSH]。

专家意见

人类的代谢组学证据表明，氨基酸代谢，能量代谢和脂质代谢是MDD病因中观察到的主要代谢改变，动物模型在该领域具有重要的理论意义。代谢组学为MDD的发病机理和治疗反应提供了新的思路。但是，研究结果并不总是一致的。代谢组学结果在临床实践中的应用将需要整合不同的生物样品和其他组学研究，以及对研究结果进行临床验证。